A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Applied Bionics and Biomechanics |
| Online Access: | http://dx.doi.org/10.1155/2022/8537966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568452554948608 |
|---|---|
| author | Jin Bian Yan Niu Yanli Ma Fuhua Chen Ning Ma |
| author_facet | Jin Bian Yan Niu Yanli Ma Fuhua Chen Ning Ma |
| author_sort | Jin Bian |
| collection | DOAJ |
| description | Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got considerable attention of clinicians for cancer treatment in recent years due to proven success of PD-1/PD-L 1 inhibition in solid tumors trials. The distinct immunological environment of EBV-associated NPC presents a reasonable therapeutic target for PD-1/PD-L 1 inhibition. Immune checkpoint blockade therapy targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L 1) receptors have shown efficacy in early phase I clinical trials, with ongoing phase III clinical trials. Herein, we have extensively addressed the role of the PD-1/PD-L1 axis in the immunotherapy of EBV-associated NPC. Immunotherapeutic strategies are anticipated to enter mainstream clinical practise and provide long-term remissions in patients with severe NPC. |
| format | Article |
| id | doaj-art-ae496489d6e9451ba1ec78a862258663 |
| institution | Kabale University |
| issn | 1754-2103 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Applied Bionics and Biomechanics |
| spelling | doaj-art-ae496489d6e9451ba1ec78a8622586632025-02-03T00:59:06ZengWileyApplied Bionics and Biomechanics1754-21032022-01-01202210.1155/2022/8537966A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma ImmunotherapyJin Bian0Yan Niu1Yanli Ma2Fuhua Chen3Ning Ma4Department of OtorhinolaryngologyDepartment of OtorhinolaryngologyDepartment of OtorhinolaryngologyDepartment of OtorhinolaryngologyDepartment of OtorhinolaryngologyEpstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got considerable attention of clinicians for cancer treatment in recent years due to proven success of PD-1/PD-L 1 inhibition in solid tumors trials. The distinct immunological environment of EBV-associated NPC presents a reasonable therapeutic target for PD-1/PD-L 1 inhibition. Immune checkpoint blockade therapy targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L 1) receptors have shown efficacy in early phase I clinical trials, with ongoing phase III clinical trials. Herein, we have extensively addressed the role of the PD-1/PD-L1 axis in the immunotherapy of EBV-associated NPC. Immunotherapeutic strategies are anticipated to enter mainstream clinical practise and provide long-term remissions in patients with severe NPC.http://dx.doi.org/10.1155/2022/8537966 |
| spellingShingle | Jin Bian Yan Niu Yanli Ma Fuhua Chen Ning Ma A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy Applied Bionics and Biomechanics |
| title | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
| title_full | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
| title_fullStr | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
| title_full_unstemmed | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
| title_short | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
| title_sort | review on the application of pd 1 blockade in ebv associated nasopharyngeal carcinoma immunotherapy |
| url | http://dx.doi.org/10.1155/2022/8537966 |
| work_keys_str_mv | AT jinbian areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT yanniu areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT yanlima areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT fuhuachen areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT ningma areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT jinbian reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT yanniu reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT yanlima reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT fuhuachen reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT ningma reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy |